KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EPS (Weighted Average and Diluted) (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 125.93% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.68 through Dec 2025, down 151.52% year-over-year, with the annual reading at -$0.68 for FY2025, 151.52% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.07 at Supernus Pharmaceuticals, up from -$0.8 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.69 in Q3 2024, with the low at -$0.8 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.13, with a median of $0.12 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 1900.0% in 2024, then crashed 8268.95% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.04 in 2021, then surged by 950.0% to $0.42 in 2022, then tumbled by 95.24% to $0.02 in 2023, then surged by 1250.0% to $0.27 in 2024, then tumbled by 125.93% to -$0.07 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.07, -$0.8, and $0.4 for Q4 2025, Q3 2025, and Q2 2025 respectively.